Summary

Genome Editing Market – Scope of Report
TMR’s report on the global genome editing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global genome editing market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global genome editing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the genome editing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global genome editing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global genome editing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global genome editing market.

The report delves into the competitive landscape of the global genome editing market. Key players operating in the global genome editing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global genome editing market profiled in this report.

Key Questions Answered in Global genome editing market Report
• What is the sales/revenue generated by wearable injectors across all regions during the forecast period?
• What are the opportunities in the global genome editing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Genome Editing Market – Research Objectives and Research Approach
The comprehensive report on the global genome editing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global genome editing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global genome editing market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Genome Editing Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Genome Editing Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario
5.2. Technological Advancements
5.3. Covid-19 Pandemic Impact on Industry
6. Global Genome Editing Market Analysis and Forecasts, By Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Technology, 2017-2031
6.3.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
6.3.2. Transcription activator-like effector nuclease (TALEN)
6.3.3. Zinc finger nuclease (ZFN)
6.3.4. Other technologies
6.4. Market Attractiveness By Technology
7. Global Genome Editing Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2017-2031
7.3.1. Cell Line Editing
7.3.2. Animal Genome Editing
7.3.3. Plant Genome Editing
7.3.4. Others
7.4. Market Attractiveness By Application
8. Global Genome Editing Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2017-2031
8.3.1. Pharmaceutical Companies and Biotechnology Companies
8.3.2. Academics and Government Research Institutes
8.3.3. Clinical Research Organizations
8.4. Market Attractiveness By End-user
9. Global Genome Editing Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Genome Editing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Technology, 2017-2031
10.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
10.2.2. Transcription activator-like effector nuclease (TALEN)
10.2.3. Zinc finger nuclease (ZFN)
10.2.4. Other technologies
10.3. Market Value Forecast By Application, 2017-2031
10.3.1. Cell Line Editing
10.3.2. Animal Genome Editing
10.3.3. Plant Genome Editing
10.3.4. Others
10.4. Market Value Forecast By End-user, 2017-2031
10.4.1. Pharmaceutical Companies and Biotechnology Companies
10.4.2. Academics and Government Research Institutes
10.4.3. Clinical Research Organizations
10.5. Market Value Forecast By Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Technology
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Genome Editing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Technology, 2017-2031
11.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
11.2.2. Transcription activator-like effector nuclease (TALEN)
11.2.3. Zinc finger nuclease (ZFN)
11.2.4. Other technologies
11.3. Market Value Forecast By Application, 2017-2031
11.3.1. Cell Line Editing
11.3.2. Animal Genome Editing
11.3.3. Plant Genome Editing
11.3.4. Others
11.4. Market Value Forecast By End-user, 2017-2031
11.4.1. Pharmaceutical Companies and Biotechnology Companies
11.4.2. Academics and Government Research Institutes
11.4.3. Clinical Research Organizations
11.5. Market Value Forecast By Country, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Technology
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country
12. Asia Pacific Genome Editing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Technology, 2017-2031
12.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
12.2.2. Transcription activator-like effector nuclease (TALEN)
12.2.3. Zinc finger nuclease (ZFN)
12.2.4. Other technologies
12.3. Market Value Forecast By Application, 2017-2031
12.3.1. Cell Line Editing
12.3.2. Animal Genome Editing
12.3.3. Plant Genome Editing
12.3.4. Others
12.4. Market Value Forecast By End-user, 2017-2031
12.4.1. Pharmaceutical Companies and Biotechnology Companies
12.4.2. Academics and Government Research Institutes
12.4.3. Clinical Research Organizations
12.5. Market Value Forecast By Country, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Technology
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country
13. Latin America Genome Editing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Technology, 2017-2031
13.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
13.2.2. Transcription activator-like effector nuclease (TALEN)
13.2.3. Zinc finger nuclease (ZFN)
13.2.4. Other technologies
13.3. Market Value Forecast By Application, 2017-2031
13.3.1. Cell Line Editing
13.3.2. Animal Genome Editing
13.3.3. Plant Genome Editing
13.3.4. Others
13.4. Market Value Forecast By End-user, 2017-2031
13.4.1. Pharmaceutical Companies and Biotechnology Companies
13.4.2. Academics and Government Research Institutes
13.4.3. Clinical Research Organizations
13.5. Market Value Forecast By Country, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Technology
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country
14. Middle East & Africa Genome Editing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Technology, 2017-2031
14.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
14.2.2. Transcription activator-like effector nuclease (TALEN)
14.2.3. Zinc finger nuclease (ZFN)
14.2.4. Other technologies
14.3. Market Value Forecast By Application, 2017-2031
14.3.1. Cell Line Editing
14.3.2. Animal Genome Editing
14.3.3. Plant Genome Editing
14.3.4. Others
14.4. Market Value Forecast By End-user, 2017-2031
14.4.1. Pharmaceutical Companies and Biotechnology Companies
14.4.2. Academics and Government Research Institutes
14.4.3. Clinical Research Organizations
14.5. Market Value Forecast By Country, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Technology
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Merck KGaA
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Takara Bio Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Cellectis SA
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. CRISPR Therapeutics
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Cibus Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. RECOMBINETICS
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Sangamo Therapeutics
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Thermo Fisher Scientific, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview